Dyadic International, Inc
Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. With a history dating back to 1979, Dyadic has evolved from industrial textiles to biotechnology, developing proprietary platforms like C1 and Dapibus™ based on the fungus Thermothelomyces heterothallica. The company aims to develop and commercialize vaccines, therapeutics, and biologic products, collaborating with partners worldwide to accelerate biopharmaceutical development and manufacturing. Dyadic is publicly listed on NASDAQ under the ticker DYAI.
Industries
Nr. of Employees
medium (51-250)
Dyadic International, Inc
1044 North U.S. Highway One, Suite 201, Jupiter, FL 33477-5094, USA
Patents
Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US-9862956-B2
View Details
Expression and high-throughput screening of complex expressed DNA libraries in filamentous fungi
US-9862956-B2
View DetailsProducts
Filamentous fungal-derived protein expression platform
A genetically engineered thermophilic filamentous fungal production system designed for high-yield recombinant protein expression and industrial-scale biomanufacturing, with demonstrated glycoengineering capability and rapid cell-line development workflows.
Filamentous fungal platform for alternative proteins and biomaterials
A microbial production platform adapted to manufacture non-pharmaceutical proteins, metabolites and biomaterials at commercial scale for food, nutrition, cosmetic and industrial applications.
Host-cell-protein (HCP) immunoassay and impurity characterization service
Qualified immunoassay and associated characterization workflows for quantification and identification of host-cell protein impurities derived from filamentous fungal production strains to support purification monitoring and regulatory lot-release.
Filamentous fungal-derived protein expression platform
A genetically engineered thermophilic filamentous fungal production system designed for high-yield recombinant protein expression and industrial-scale biomanufacturing, with demonstrated glycoengineering capability and rapid cell-line development workflows.
Filamentous fungal platform for alternative proteins and biomaterials
A microbial production platform adapted to manufacture non-pharmaceutical proteins, metabolites and biomaterials at commercial scale for food, nutrition, cosmetic and industrial applications.
Host-cell-protein (HCP) immunoassay and impurity characterization service
Qualified immunoassay and associated characterization workflows for quantification and identification of host-cell protein impurities derived from filamentous fungal production strains to support purification monitoring and regulatory lot-release.
Services
Licensing, technology transfer planning and execution to support local manufacturing, cGMP readiness and regulatory pathway alignment for partner regions.
Joint programs to develop vaccine antigens, monoclonal antibodies and other recombinant therapeutics using filamentous fungal expression hosts, including preclinical and early clinical support and out-licensing pathways.
Provision and qualification of HCP immunoassays and impurity characterization services using antibody-affinity extraction and mass spectrometry to support purification monitoring and lot-release testing.
Provision of processes and programmatic support for cGMP production, transfer of manufacturing protocols and supply of clinical trial material for early-phase studies.
Grant-supported projects to benchmark platform speed and scalability versus established mammalian systems and to develop rapid cell-line generation workflows for antibody production.
Licensing, technology transfer planning and execution to support local manufacturing, cGMP readiness and regulatory pathway alignment for partner regions.
Joint programs to develop vaccine antigens, monoclonal antibodies and other recombinant therapeutics using filamentous fungal expression hosts, including preclinical and early clinical support and out-licensing pathways.
Provision and qualification of HCP immunoassays and impurity characterization services using antibody-affinity extraction and mass spectrometry to support purification monitoring and lot-release testing.
Provision of processes and programmatic support for cGMP production, transfer of manufacturing protocols and supply of clinical trial material for early-phase studies.
Grant-supported projects to benchmark platform speed and scalability versus established mammalian systems and to develop rapid cell-line generation workflows for antibody production.
Expertise Areas
- Microbial expression platform development
- Glycoengineering for biotherapeutics
- Biopharmaceutical manufacturing (cGMP)
- Fermentation process development and scale-up
Key Technologies
- Filamentous fungal-based gene expression
- Glycoengineering for human-like N‑glycans
- Strain engineering and mutagenesis
- Fermentation and bioreactor scale-up